In conclusion, we constructed a three-gene calssifier (involving FAM72B, GNE, and TRIM46) with comprehensive prognostic ability to predict both clinical recurrence and BCR for PCa patients after RP. This evidence concerns the gene TRIM46 and posterior cortical atrophy.